U.S. Cancer Deaths Drop While New Cases Increase, Roundup Reports
CDC data show U.S. cancer deaths fell from 2019 to 2023, largely because of fewer lung cancer fatalities, even as new cancer diagnoses increased. The roundup also covers a dissolving microneedle patch for chemotherapy delivery, a finding that type 2 diabetes doubled cancer risk, and several drug and trial updates. Other items include FDA approval of belzutifan plus lenvatinib for advanced renal cell carcinoma and trial results for teclistamab plus daratumumab in multiple myeloma.
CDC figures show U.S. cancer deaths declined from 2019 through 2023, mostly because fewer people died of lung cancer, while new diagnoses increased. The roundup also describes a dissolvable microneedle array made by 3D printing that delivered chemotherapy in an early test, and research indicating type 2 diabetes was associated with about double the cancer risk.
Separately, the FDA approved belzutifan plus lenvatinib for advanced kidney cancer with clear cell features after earlier treatment, and trial data suggested many patients with multiple myeloma that had returned or resisted treatment might live as long as similar people without the disease when given teclistamab plus daratumumab.
Falling deaths may reassure patients and families, but rising cases could increase demand for screening, treatment, and survivorship care. New delivery methods and drug approvals may expand options, though access and cost remain considerations. Diabetes-linked risk could prompt closer cancer surveillance among affected people. Trial logistics and funding shifts may influence which patients can join studies. These developments could shape care experiences, but actual impact depends on implementation, affordability, and evidence.